Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3681-3700 of 3,900 trials

Rheumatoid Arthritis: Lower Dose of Rituximab Study

We are evaluating whether a 200 mg dose of Rituximab every six months is as effective as the standard 1 g dose for managing rheumatoid arthritis. This study will help us understand its impact on disease activity and overall patient well-being.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementRheumatology

FT751: Safety and Tolerability Study

We are examining a new oral medication, FT751, in healthy individuals to understand its safety and how it is processed in the body. This research may help inform future treatments.

Autoimmune Disorders6-12 monthsSafety phase (I)Rheumatology

Breast Cancer Prevention: Exemestane vs. Tamoxifen

We are comparing two low-dose medications for post-menopausal women at high risk for breast cancer to see which one may improve quality of life and hormonal balance. This study aims to understand their effects over 12 months.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Bladder Cancer: EMDA-MMC Treatment Study

We are evaluating a new treatment using electric current to deliver mitomycin C for high-grade non-muscle invasive bladder cancer. This study compares its effectiveness and safety to the standard BCG therapy.

Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Chronic Urticaria: Study of BLU-808

We are testing a new medication, BLU-808, for people with chronic inducible and spontaneous urticaria. The study aims to understand its safety and how well it may help reduce symptoms.

Chronic Urticaria3-6 monthsEfficacy phase (II)Investigational MedicinesAllergologyDermatology

Small-Cell Lung Cancer: Tarlatamab Combination Study

We are testing a new treatment combining tarlatamab with durvalumab, carboplatin, and etoposide for patients with untreated extensive stage small-cell lung cancer. The goal is to see if this combination helps improve survival compared to standard treatment.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Breast Cancer Treatment: Elacestrant Study

We are studying whether Elacestrant alone is as effective as Elacestrant with ovarian function suppression in premenopausal women with early-stage ER+/HER2- breast cancer. The trial also looks at the safety of these treatment options.

Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

CEB-01 for Pediatric Abdominal Tumors

We are testing a new treatment for children with certain types of abdominal tumors to see if it is safe and effective alongside standard care. This study focuses on children from birth to under 18 years old.

Desmoplastic Small Round Cell TumorFibrolamellar Hepatocellular CarcinomaExtracranial Malignant Rhabdoid Tumor6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOncologyPediatrics

Psoriasis in Children: IDP-122 Lotion Study

We are testing a new lotion for children with moderate to severe plaque psoriasis to see how safe it is and how well it is absorbed into the body. This study will help us understand its effects on children's hormonal systems.

Plaque Psoriasis≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyEndocrinology

Exenatide for Early Parkinson’s Disease Progression

We are studying whether Exenatide can slow down the progression of symptoms in people with early Parkinson’s disease. The trial will also assess the safety of this treatment over time.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyNeurology

Bisphosphonate Treatment for Primary Hyperparathyroidism

We are studying whether bisphosphonate treatment before parathyroid surgery can improve bone, kidney, and heart health one year after the procedure. This trial compares the treatment to a placebo to see if there are any benefits.

Primary Hyperparathyroidism1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Clonidine for Preventing Agitation in Young Children After Anesthesia

We are studying whether clonidine can help reduce agitation and pain in children under one year after surgery. The trial also examines its safety and effects on nausea and opioid use.

Postoperative Agitation≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyPediatrics

Cancer Treatment: NTX-1088 and Pembrolizumab

We are studying the effects of NTX-1088 alone and with Pembrolizumab in patients with cancer. The goal is to see if this combination improves treatment outcomes.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Stem Cell Transplant: New T Cell Therapy

We are studying a new treatment using special T cells to help prevent complications in patients receiving stem cell transplants from siblings. The goal is to see if this approach can safely reduce the need for other medications.

Healthy Participants6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal Medicine

Daratumumab for Myalgic Encephalomyelitis (ME/CFS)

We are studying whether the drug daratumumab can help reduce symptoms in people with moderate to severe ME/CFS. The trial will also assess its safety compared to a placebo.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesNeurology

Lung Cancer: Nivolumab with Ipilimumab and Chemotherapy

We are studying a new way to administer nivolumab alongside ipilimumab and chemotherapy for patients with untreated metastatic or recurrent lung cancer. The trial aims to understand how the body reacts to this combination and its safety.

Non-small cell lung cancer6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

PMM2-CDG: GLM101 Treatment Study

We are investigating whether weekly doses of GLM101 can improve movement and coordination in people with PMM2-CDG. The study will also evaluate the safety of this new treatment compared to a placebo.

Congenital Disorder of Glycosylation (CDG)6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHepatologyNeurology

Hairy Cell Leukemia: Vemurafenib and Rituximab Study

We are exploring a new treatment combination for hairy cell leukemia that may be less toxic than standard chemotherapy. This study aims to see if it is just as effective while monitoring patient safety and quality of life.

Hairy Cell Leukaemia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Hodgkin Lymphoma: Ruxolitinib with Brentuximab or Pembrolizumab

We are studying the combination of ruxolitinib with either brentuximab or pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma. The goal is to see if this combination improves treatment response and safety.

Recurrent or Refractory Classical Hodgkin Lymphoma3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Brain Disorders: NT 0150 Study

We are investigating a new compound, NT 0150, for its safety and how it is absorbed and eliminated in the body. This research may help in developing treatments for Alzheimer's and Parkinson's disease.

Cryopyrin Associated Periodic Syndrome6-12 monthsSafety phase (I)Internal MedicineNeurology